{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ATEMPT 2.0","nct_id":"NCT04893109","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=atempt-2-0-nct04893109. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Randomized participants will receive intravenous T-DM1 every 3 weeks for 6 cycles (18 weeks) and then Trastuzumab SC (subcutaneous) every 3 weeks for 11 cycles","label":"Arm A. T-DM1 followed by Trastuzumab SC","type":"EXPERIMENTAL"},{"description":"Randomized participants will receive weekly intravenous Paclitaxel for 12 weeks (4 cycles) and Trastuzumab SC (subcutaneous) every 3 weeks for 17 cycles. The first 4 doses Trastuzumab SC are given with Paclitaxel.","label":"Arm B: Paclitaxel with Trastuzumab SC, followed by Trastuzumab SC alone","type":"EXPERIMENTAL"}],"collaborators":["Genentech, Inc."],"completion_date":{"date":"2029-05-01","type":"ESTIMATED"},"conditions":["Breast Cancer","HER2-positive Breast Cancer"],"enrollment":{"count":500,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"trastuzumab-emtansine","otherNames":["T-DM1","Kadcyla"],"type":"DRUG"},{"name":"Trastuzumab SC","otherNames":["Herceptin Hylecta"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol","Onxal"],"type":"DRUG"}],"last_update":"2026-08-19","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of clinically relevant toxicities (CRT)","timeFrame":"First 18 weeks of treatment"},{"measure":"Disease Free Survival (DFS)","timeFrame":"Time from randomization to first Disease Free Survival (DFS) event up to 72 months"}],"references":[],"start_date":{"date":"2021-06-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","url":"https://clinicaltrials.gov/study/NCT04893109"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/atempt-2-0-nct04893109"}